Pre-clinical studies provide strong evidence that Q-Cells® have the potential to restore neuron function and improve survival in neurodegenerative diseases
In Diseases Involving Neuron Damage
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) is a neurodegenerative disease that affects motor neurons, the nerve cells in the brain and spinal cord that control muscle movement. The progressive degeneration of motor neurons caused by ALS eventually leads to motor neuron demise. The most common cause of death among ALS patients is respiratory failure, which occurs when nerve damage eventually affects the muscles that control breathing.
In animal models of ALS, transplantation of Q-Cells® has shown that Q-Cells® localize to motor neurons in the spinal cord, positioned to rescue those neurons that are at risk.
Studies have also shown enhanced survival and motor function in ALS rats treated with the rat homolog of Q-Cells®.
In Diseases Involving Myelin Deficiency (Glial Cell Damage)
Demyelinating diseases, such as multiple sclerosis and transverse myelitis, occur when myelin-producing oligodendrocytes are damaged or destroyed. In animal models of myelin deficiency, transplantation of Q-Cells® has been shown to give rise to oligodendrocytes that are able to produce functional, widespread myelination and associated survival benefit.
Unlike neurons, Q-Cells® can migrate, enabling them to travel to and target sites of CNS injury or disease.
Based on numerous, promising laboratory and animal studies, we are actively preparing for a clinical trial of Q-Cells® in human patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). We have received FDA clearance to proceed and expect to begin that trial in 2016.
Based on numerous, promising laboratory and animal studies, we are actively preparing for a clinical trial of Q-Cells® in human patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), and expect to begin that trial in 2015.